Publications by authors named "G Lorenzon"
Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria.
View Article and Find Full Text PDFUstekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.
View Article and Find Full Text PDFArticle Synopsis
- Therapeutic drug monitoring (TDM) for anti-tumor necrosis factor (anti-TNF) treatments in inflammatory bowel disease (IBD) can improve treatment outcomes and manage failures more cost-effectively, but slow lab results hinder its widespread use.
- *To address this issue, point-of-care technology tests (POCTs) offer rapid results at the patient's location, allowing for faster treatment decisions compared to the current standard method, the ELISA assay.
- *This study evaluated a new POCT method (ProciseDx) against the standard ELISA method for measuring drug levels in IBD patients and found a strong correlation between the two, suggesting the POCT could be a practical alternative in clinical settings.*
Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.
Clin Exp Gastroenterol
October 2024
Crohn's disease (CD) is a complex, chronic inflammatory bowel disease characterized by unpredictable flare-ups and periods of remission. Despite advances in treatment, CD remains a significant health burden, leading to substantial direct healthcare costs and out-of-pocket expenses for patients, especially in the first-year post-diagnosis. The impact of CD on patients' quality of life is profound, with significant reductions in physical, emotional, and social well-being.
View Article and Find Full Text PDFIntroduction: Frontal and/or parietal atrophy has been reported during aging. To disentangle the heterogeneity previously observed, this study aimed to uncover different clusters of grey matter profiles and trajectories within cognitively unimpaired individuals.
Methods: Structural magnetic resonance imaging (MRI) data of 307 Aβ-negative cognitively unimpaired individuals were modelled between ages 60-85 from three cohorts worldwide.